Axomadol
 | |
| Clinical data | |
|---|---|
| ATC code | None |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number |
187219-95-0 187219-99-4 |
| PubChem (CID) | 10221318 |
| ChemSpider | 8396810 |
| Chemical and physical data | |
| Formula | C16H25NO3 |
| Molar mass | 279.375 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
Axomadol (INN, USAN) (code name EN3324) is a synthetic, centrally-acting opioid analgesic of the benzenoid class which was under investigation by Endo Pharmaceuticals in collaboration with Grünenthal for the treatment of chronic, moderate to severe lower back pain and arthrosis.[1][2] Development was halted after phase II clinical trials as it did not meet the pre-determined clinical endpoints.[3]
See also
References
- ↑ Chadds Ford (2011-06-30). "Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain" (Press release). Endo Pharmaceuticals. Retrieved 2012-05-11.
- ↑ US Abandoned 20100331424, Schiene K, Bloms-Funke P, Bothmer J, Lefeber C, "Use of Axomadol for Treatment of Arthrosis Pain", published 2010-12-30, assigned to Grünenthal GmbH
- ↑ Chadds Ford (2011-08-17). "Endo Pharmaceuticals Announces Termination of Collaboration with Grunenthal for the Development of Axomadol" (Press release). Endo Pharmaceuticals. Retrieved 2012-05-11.
| Opioids | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Paracetamol-type |
| ||||||||||||||||||||||||||||||
| NSAIDs |
| ||||||||||||||||||||||||||||||
| Cannabinoids | |||||||||||||||||||||||||||||||
| Ion channel modulators |
| ||||||||||||||||||||||||||||||
| Myorelaxants | |||||||||||||||||||||||||||||||
| Others | |||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.